News
08/11/2026
Pascal Medical Corporation Secures $3.8M to Advance ClickGel Into Pivotal Large Animal Testing
Pascal Medical Corporation has raised $3.8 million to push its ClickGel surgical sealant through pivotal large animal testing on the way to human trials. The total combines a $3 million private financing round closed in July with an $800,000 grant from Virginia Catalyst, announced by Governor Abigail Spanberger on July 30, 2026. Pascal will use …
08/10/2026
Expanding visibility with wearable blood pressure monitoring: CareTaker
In higher-risk patient populations, across all points of care, a patient’s condition can deteriorate quickly between routine vital sign checks, creating critical gaps in visibility and leaving clinical deterioration undetected between rounds. Continuous clinical-grade non-invasive blood pressure (CNIBP) monitoring, combined with hemodynamic trending, helps close these gaps by providing a more complete view of patient …
08/10/2026
BIO-CAT Joins the Lallemand Family
BIO-CAT is pleased to join the Lallemand family as we begin an exciting new chapter together. Effective July 31, 2026, Lallemand Inc. has completed its acquisition of BIO-CAT Enzymes & Microbials. Together, we are combining complementary expertise in enzymes, microbial technologies, fermentation, and life science innovation to create an even stronger platform for developing next-generation …
08/05/2026
Virginia Catalyst Announces Opening of Grant Round 20
The Virginia Catalyst announced that it is accepting letters of intent (LOI) for Grant Round 20 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The Virginia Catalyst is excited to open Grant Round 20 to continue our support of Virginia’s …
08/04/2026
Capra advances domestic manufacturing of essential medicines with continued HHS support
Capra Biosciences, Inc., a biomanufacturing company leveraging modular, continuous bioreactor technology to enable flexible, cost-competitive domestic production of pharmaceutical ingredients, today announced continued progress under its project agreement with the Administration for Strategic Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS). The additional investment brings Capra’s total ASPR …
08/04/2026
BRAINBox Solutions Announces Strategic Financing to Advance Development of Point-of-Care Concussion Diagnostic/Prognostics
BRAINBox Solutions today announced a strategic financing to accelerate the development of point-of-care (PoC) and lab-based devices for its BRAINBox TBI diagnostic/prognostic tests for concussion (also known as mTBI or Acute Traumatic Encephalopathy). The financing included equity funding as well as credit facilities from Pivotal Capital Partners and New Horizon Bank. Specific terms were not …
08/03/2026
Kaléo Announces License Agreement with Amgen for Auto-Injector Technology
Kaléo announced that it has entered into a confidential license agreement with Amgen Inc. Under the terms of the agreement, Amgen obtained a license to certain of Kaléo’s patented technology on auto-injectors. This agreement reflects Kaléo’s innovative contribution to drug-device technologies and longstanding leadership in advancing patient-centric auto-injector solutions. Financial and other terms of the …
08/03/2026
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that they have entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceutical company with significant scale. The transaction is expected to generate significant value for stockholders …
07/30/2026
Governor Spanberger Announces $2.4 Million in Grants for Virginia’s Biomedical Innovation Ecosystem
Governor Abigail Spanberger today announced a $2.4 million investment in Virginia’s life sciences ecosystem through Virginia Catalyst’s highly competitive grant program. Virginia Catalyst was founded in 2013 as Virginia’s research consortium through the efforts of the Virginia General Assembly and five of Virginia’s premiere research institutions. These non-dilutive grants — funding that does not require …
07/29/2026
Slone Partners Names Sona Stroud and Kim Wilson as Senior Partners
Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, today announced the appointments of Sona Stroud and Kim Wilson as Senior Partners. Stroud has been promoted to the role following nearly 15 years with the firm, while Wilson returns to the organization, further strengthening its leadership team with nearly 17 years …
07/28/2026
NanOptical Biomedical Commercializes Cancer Imaging Technology
NanOptical Biomedical Inc., a biotechnology company working on next-generation contrast agents for photoacoustic imaging, has started operations at the Endeavor incubator in Innovation Park, Manassas. The company will manufacture SonoVanta™, a patent-pending contrast agent that improves the precision of cancer margin imaging, supporting more accurate biopsies and tumor removal. SonoVanta™ originated from research conducted at …
07/23/2026
Activation Capital Expands the Bio+Tech Center, Doubling Laboratory Capacity to Strengthen Virginia’s Life Sciences Entrepreneurship and Innovation Ecosystem
Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced an expansion of its Bio+Tech Center to support the continued growth of life sciences entrepreneurship across the region. Activation Capital’s Bio+Tech Center is a life sciences incubator located within the Virginia Bio+Technology Research Park. Serving as both a physical and programmatic …
07/22/2026
Epidarex Announces Leadership Appointments
With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen our impact across the US and UK life science ecosystems, recognizing and elevating exceptional talent within our team is a vital part of that journey. These transitions reflect our continued …
07/22/2026
Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer
Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO), dedicated to strengthening the nation’s pharmaceutical supply chain and protecting America’s medicine cabinet, today announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer. Venkatraman brings more than 25 years of experience in pharmaceutical development, process chemistry, manufacturing, and scientific leadership. He …
07/20/2026
Virginia’s Advanced Pharmaceutical Manufacturing Tech Hub Secures Federal Investment to Launch End-to-End Commercialization Project
Alliance for Building Better Medicine, the coalition leading Virginia’s Advanced Pharmaceutical Manufacturing (APM) Tech Hub, today announced a $15.97 million investment from the U.S. Economic Development Administration (EDA) to launch the End-to-End (E2E) Commercialization Project. The initiative will help establish a domestic commercialization pathway connecting innovation, manufacturing, and patients. Led by Civica, Inc. (Civica Rx) …
07/15/2026
Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award
Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s …
07/14/2026
ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases
The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE …
07/09/2026
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin …
07/07/2026
United Therapeutics Corporation Acquires Thymmune Therapeutics
United Therapeutics Corporation (Nasdaq: UTHR) announced it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the …
07/07/2026
Governor Spanberger Announces Virginia Ranked #1 in Nation for Customized Workforce Training
Governor Abigail Spanberger announced today that Virginia is ranked number one in the United States for customized workforce training in the 22nd annual Business Facilities Rankings Report for the fourth consecutive year. Business Facilities, a leading national publication for economic development professionals, recognized the Virginia Talent Accelerator Program for its success in delivering workforce training …
07/05/2026
LifeNet Health, NASA, and UNOS Complete First-of-Its-Kind Drone Kidney Transport Study to Help Save More Lives
Teams from the United Network for Organ Sharing (UNOS), NASA Langley Research Center, and LifeNet Health successfully completed a groundbreaking study transporting human kidneys by drone beyond visual line of sight, marking a major milestone in the future of organ transportation and transplantation. The June 5 flights highlight the potential for drone technology to support …
06/29/2026
Stemora receives NSF SBIR Phase I award to advance breakthrough cartilage regeneration technology
Stemora Inc., a Maryland-based biotechnology company developing next-generation regenerative therapies for osteoarthritis and cartilage injuries, today announced that it has been awarded a $305,000 National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant. The award supports Stemora’s development of a one-step, intraoperative regenerative therapy designed to restore durable hyaline cartilage by activating …
06/23/2026
Scout Space raises Series A second close from VTC Ventures, Long Knife, and 100KM
Scout Space, a space domain awareness sensor and software provider, has announced the second close of its Series A financing, adding VTC Ventures, Long Knife and 100KM to its investor syndicate. The initial close occurred in May 2026, led by Washington Harbour Partners. The funding will accelerate deployment of Scout’s in-orbit sensor network, support upcoming …
06/22/2026
Icarus Medical Secures $7.2 Million Series A to Accelerate Growth and Innovation
Icarus Medical, a Charlottesville-based med-tech company focused on advancing orthopedic bracing technology, today announced the successful close of its Series A financing round. Originally targeting $5 million, the round closed oversubscribed at $7.2 million, reflecting strong investor confidence in the company’s technology platform, market momentum, and long-term vision. Orthopedic bracing company Icarus Medical closes oversubscribed …
06/16/2026
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company’s newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options to purchase Company common stock as an inducement to …